Overview of Tempas

Tempas: What It Is

Property	Description
Active Ingredients	Metamizole sodium trihydrate, Temazepam
Form	Oral Solid Preparation (e.g., tablet or capsule)
Pharmacological Class	Hypnotic-Analgesic Combination
Common Use	Simultaneous pain relief and sedation
Origin	Synthetic compound

Tempas: Identity, Type, and Classification

Tempas is defined as a specialized Hypnotic-Analgesic Combination, a single medication engineered to deliver simultaneous pain relief and sedation via the oral route. This pharmaceutical product is a synthetic compound, typically provided as an oral solid preparation. Its design uniquely targets the co-occurrence of severe discomfort and sleep deprivation, positioning it apart from single-action treatments. The classification as a Hypnotic-Analgesic Combination is clinically recognized for addressing painful states that are compounded by debilitating insomnia, a scenario where the dual-action formulation offers a necessary, unified therapeutic strategy.

What is Tempas Made Of? Composition and Component Classes

The composition of Tempas is centered on two distinct active ingredients: metamizole sodium trihydrate and temazepam. Metamizole is classified as a pyrazolone derivative, providing potent analgesic and antipyretic properties. Temazepam is a Benzodiazepine primarily known for its hypnotic and sedative actions on the central nervous system. The inclusion of both an established pain reliever and a controlled central nervous system depressant ensures that the formulation targets both the physical discomfort and the neurological disturbance, a unique feature of this specific combination.

What is the General Purpose of This Combination Drug?

The general purpose of the Tempas combination is to provide a dual therapeutic effect for the simultaneous management of pain and sleep disturbances. The core benefit is achieved through the intended synergistic effect of the components, where the potent analgesic action of metamizole is complemented by the strong calming and sleep-inducing action of temazepam. This combined approach facilitates effective pain management and the profound sedation required to resolve the cycle where severe discomfort prevents restorative rest, a typical use scenario being acute musculoskeletal pain accompanied by consequential insomnia.

Regulatory References

FDA Temazepam Label

What side effects are possible with Tempas?

Possible Side Effects and Safety Information

The officially documented safety profile for Tempas is defined by risks associated with both its analgesic (Metamizole) and hypnotic (Temazepam) components, classified by government regulatory authorities into distinct categories.

Adverse reactions are formally grouped by System-Organ Class (SOC). Nervous System Disorders are frequently reported, predominantly reflecting the sedative actions of Temazepam. Blood and Lymphatic System Disorders and Immune System Disorders are associated with the Metamizole component.

Serious adverse reactions listed in regulatory documents include Agranulocytosis (a rare but life-threatening blood disorder associated with Metamizole) and severe hypersensitivity reactions such as Anaphylactic Shock. The Temazepam component carries the serious risk of developing physical and psychological dependence.

Frequency Classification and Expected Reactions

Side effects are classified using standard regulatory frequency bands:

Common Reactions: These typically involve the Central Nervous System, such as drowsiness, sedation, and dizziness.
Rare Reactions: These include Agranulocytosis and Anterograde Amnesia.

Population-Specific Constraints

Official labeling mandates specific safety considerations for certain patient groups. Older adults may exhibit increased sensitivity to CNS depression, which elevates the documented risk of falls. The use is also restricted or cautioned in patients with significant renal or hepatic impairment, due to the potential for reduced clearance of the active substances. Additionally, the risk of dependence is officially stated to increase significantly with the duration of use of the Temazepam component.

Overdose and Emergency Response

Tempas Overdose and When to Seek Help

The official overdose profile for Tempas is characterized by the combined risks associated with its two components: severe Central Nervous System (CNS) depression and the potential for serious systemic and organ damage, strictly based on regulatory documents.

Documented Manifestations and Outcomes

Feature	Official Regulatory Statements
Manifestations	Profound Sedation, Extreme Sleepiness, Confusion, Hypotension, Absent Reflexes, Ataxia, Slurred Speech.
Life-Threatening	Respiratory Depression, Coma, and Death (especially when co-ingested with other CNS depressants). Acute Liver Failure and Agranulocytosis are noted risks.
Vulnerable Groups	Elderly patients and those with hepatic or renal impairment have increased susceptibility to adverse overdose effects.

Emergency Actions and Management

Regulatory documents mandate that you seek immediate medical attention and call emergency services immediately if symptoms such as trouble breathing, seizure, or unresponsiveness (cannot be awakened) are observed. Hospital monitoring is required for assessment of cardiac, respiratory, and CNS function.

Management focuses on symptomatic and supportive treatment. Although the benzodiazepine component can be reversed by Flumazenil, its use carries a documented risk of seizures and re-sedation. For the Metamizole component, no specific antidote is known. Procedural steps often include limiting drug absorption through Gastric Lavage or Activated Charcoal.

Therapeutic Uses of Tempas

What Tempas Treats: Main Uses and Benefits

The Tempas combination is applied in addressing symptom clusters related to severe physical discomfort and consequential sleep disturbance. The combination leverages the established use of Metamizole, which is commonly applied in addressing symptoms related to physical discomfort and systemic imbalance, such as moderate to severe pain and fever.

The primary therapeutic benefit is that it supports the patient by addressing symptom clusters related to both severe pain and consequential sleep deprivation. It is commonly used in clinical settings that involve acute or unstable symptom patterns that require short-term symptomatic support, including postoperative discomfort, traumatic injuries, and visceral pain (colic).

“The combination is used to address symptoms that interfere with daily comfort, supporting the patient during episodes of heightened discomfort.”

The medication may assist with managing symptoms that create noticeable functional strain, contributing to easing the overall symptom load.

Quick Fact: Relevant for Symptomatic Management of Severe Acute Pain and Debilitating Insomnia

Regulatory References

European Medicines Agency on Metamizole

Eligibility and Restrictions for Use

Who Can and Cannot Use Tempas? — Official Regulatory Information

The official eligibility profile for Tempas restricts its use to the adult population (18 years and older). Use is formally not established in children and adolescents, and the medicine is not recommended for women who are breastfeeding. Older adults may require special consideration, including closer monitoring and lower starting doses, as specified in regulatory documentation.

Absolute Contraindications (Must Not Use)

Tempas is formally contraindicated in several patient groups. These absolute prohibitions include:

Women who are pregnant or may become pregnant.
Patients with a known history of benzodiazepine hypersensitivity or prior metamizole-induced agranulocytosis or related haematological disorders.
Individuals with impaired bone marrow function or haematopoietic diseases.
Patients with severe respiratory conditions such as severe hypoventilation or sleep apnea syndrome.
Patients with acute narrow-angle glaucoma.

Conditional Use Restrictions

Eligibility requires caution for patients with severe hepatic deficiencies (liver problems) or severe renal deficiencies (kidney problems). Patients with a history of substance abuse or severe depression also require a specific eligibility assessment documented in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail the interaction profile of Tempas based on its role as a substrate for metabolic enzymes and transporters, and as an inhibitor of specific enzymes. The most critical constraints relate to agents that significantly affect the concentration of Tempas in the body.

Interaction Restrictions and Classifications

Interaction Mechanism	Interacting Product Category	Regulatory Constraint
Metabolism (CYP3A4) Substrate	Strong CYP3A4 Inhibitors	Contraindicated Combination
Metabolism (CYP3A4) Substrate	Strong CYP3A4 Inducers	Avoid co-administration (potential lack of effect)
Transport (OATP1B1/1B3) Substrate	OATP Inhibitors	Use with caution; may require dose reduction

Specific Interaction-Related Requirements

Co-administration of Tempas with strong CYP3A4 inhibitors is contraindicated due to the predicted increase in Tempas exposure, which exceeds safety thresholds. Conversely, co-administration with strong CYP3A4 inducers may significantly lower Tempas exposure, potentially resulting in reduced effectiveness; this combination should be avoided.

For acid-reducing agents (e.g., antacids, PPIs, H2RAs), which may reduce Tempas absorption due to pH-dependent solubility, specific timing-based administration rules apply, requiring separation of dosing by several hours. Furthermore, because Tempas is documented as an inhibitor of the CYP2C8 enzyme, the concurrent use of sensitive CYP2C8 substrates may require a dose adjustment for the co-administered drug to prevent increased exposure of that medicine.

Mechanism of Action

Tempas acts through two distinct mechanistic domains to modulate key signaling and transcriptional pathways. The drug functions as a dual antagonist of the EP2 and EP4 prostaglandin receptors, both of which are G protein-coupled receptors. By blocking the binding of endogenous Prostaglandin E2 (PGE2) to these receptors, Tempas prevents the initiation of downstream signaling cascades that are typically associated with heightened cellular responses.

Simultaneously, Tempas engages a nuclear signaling pathway by selectively inhibiting the transcription factor Peroxisome Proliferator-Activated Receptor alpha (PPARalpha). This inhibitory action modifies early molecular steps involved in gene transcription that govern systemic metabolic and inflammatory processes. Through this dual-action mechanism—antagonizing membrane-bound receptors and inhibiting a nuclear transcription factor—Tempas influences the regulation of dysregulated cellular activity and modulates systemic pathway outcomes.

Dosage and Administration Information

The use of Tempas, an oral hypnotic-analgesic combination, is centered on its two components. Administration is restricted to the oral route as a single solid preparation. The fundamental principle is to utilize the lowest effective dose for the desired combined effect, which includes a Temazepam component dose ranging from 7.5 mg to 30 mg and a Metamizole component dose that may be up to 1,000 mg. The single daily dose must be taken immediately before bedtime to ensure the patient is ready to go to sleep.

Instruction Map: How to use Tempas — Administration Guidelines

Feature	Guideline
Route of administration:	Oral administration only.
Dosing schedule:	Use of the lowest effective single dose within established component ranges.
Timing in relation to meals (if applicable):	Generally not restricted by meals; focus is on the time-of-day requirement.
Preparation requirements (if applicable):	No preparation steps (e.g., dilution or reconstitution) are required for the oral solid preparation.
Age-group administration rules:	Older Adults must start with the lower end of the Temazepam dosing range, such as 7.5 mg.
Missed-dose rules:	A missed dose may be taken later, provided the patient can still remain asleep for the full 7 to 8 hours after administration.
Special procedural conditions:	Must be administered only when the patient is ready for sleep and can commit to 7 to 8 hours of uninterrupted rest.

Instruction Classifications (High-level)

Classification	Detail
Administration method type:	Oral (solid preparation)
Frequency pattern:	Once daily (qHS)
Use-context constraints:	Short-term use only, generally limited to 7 to 10 days.

Resulting procedural structure

Step sequence:

Take one dose immediately before the patient intends to go to sleep.
Ensure that the administration timing allows for a period of 7 to 8 hours of sleep.
After extended use, the drug must be gradually tapered off upon discontinuation.

Connection to the overall use protocol: The usage protocol for Tempas is defined by its single, oral, nocturnal dose, which standardizes the method of intake and confines its administration to the time when sedation is required. This schedule is paired with a short-term duration limit and a lowest-effective-dose principle, which collectively structure its use as a temporary solution for acute symptom patterns. The specific instructions for older adults and the tapering requirement further refine the protocol for proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tempas

Evidence for Managing Severe Acute Pain

Research into the analgesic component of Tempas, Metamizole, includes numerous short-term, placebo-controlled Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies were used in research exploring how symptoms change over time and were primarily conducted on adults experiencing moderate to severe acute pain. The outcomes observed included standardized measurements of pain intensity and the need for additional pain medication.

Studies evaluated and reported measurements of change in pain scores in the active treatment groups compared to those observed in the placebo groups within the initial observation period. However, the evidence largely focuses on short-term outcomes, and long-term effects are not fully established.

Evidence for Addressing Consequential Insomnia and Sleep Disturbance

The research base for the component classified as a hypnotic, Temazepam, is structured around short-term, double-blind, placebo-controlled RCTs. These studies primarily focused on adults with transient or short-term insomnia, including some research focused on older adults. The primary outcomes related to systemic or functional imbalance evaluated included objective measurements of the time taken to fall asleep and the total time spent sleeping.

Studies reported measurements of sleep parameters, describing observed patterns related to sleep latency and total sleep time over the brief study period (e.g., 7 to 14 consecutive nights). Despite this, the evidence is largely limited to the management of short-term sleep disturbances and research exploring temporary physiological imbalance.

Research Base for the Dual-Action Combination

The fixed-dose combination product, Tempas, is designed for use in research contexts involving fluctuating or unstable symptoms where severe acute pain is compounded by sleep disturbance. Dedicated, high-level clinical trials that specifically evaluate the precise combination of Metamizole and Temazepam are not widely documented in regulatory reviews.

This means that the rationale for the combination was explored in some studies, based on the known, separate actions of the component classified as an analgesic and the component classified as a hypnotic. Regulatory reviews generally describe a paucity of dedicated data specifically characterizing the unique profile of the fixed-dose combination product. Certainty remains low for the specific dose-response relationship of this combination, and comparative evidence is lacking.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tempas (FAQ)

Q: How quickly does Tempas usually start working?

According to the official product information, the medication typically begins to show its initial effects within about 30 minutes. The highest concentration of the drug in the blood is usually reached within three hours after administration.

Q: How long can the effects of Tempas be expected to last?

The intended therapeutic effect of the drug, which includes profound sedation, is expected to last for up to 8 hours to allow for a full night's sleep. Official data indicates that the time required for the body to reduce the drug's concentration by half (half-life) can range from 8 to 20 hours.

Q: Can Tempas be taken with common pain relievers?

Regulatory documents advise caution regarding combining Tempas with other pain relievers because it can increase associated risks. Taking it alongside strong sedating pain medications may carry an increased chance of extreme drowsiness or severe breathing difficulty.

Q: Do the side effects of Tempas usually go away over time?

Official product information focuses on the persistence of some effects, such as residual drowsiness or a 'hangover' feeling that lasts into the day following administration. This indicates that side effects are not guaranteed to disappear quickly.

Q: Is Tempas considered a controlled substance?

Yes, the Temazepam component of this combination medicine is classified as a Schedule IV controlled substance. This classification is given to drugs that have been identified as having a potential for dependence and abuse.

Q: Are there any specific foods or drinks to avoid while using Tempas?

Regulatory documents include a strong warning that consuming alcohol is discouraged while using this medication. Combining Tempas with alcohol can lead to severe side effects, including extreme drowsiness and dangerous breathing problems.

Q: Does Tempas interact with alcohol consumption?

Yes, regulatory documents strongly caution against combining Tempas with alcohol. The official warning indicates that alcohol can severely increase the central nervous system side effects of the medication, leading to problems such as extreme drowsiness, excessive sedation, and respiratory depression.

Q: Where can I find the official regulatory information about Tempas?

Official product information is available to the public in regulatory documents. These include the FDA-approved Medication Guide or Package Insert in the United States, and the Summary of Product Characteristics (SmPC) in Europe.

Q: Are there different strengths or forms of Tempas available?

The official product labeling provides details on the specific strengths and dosage forms that are available for this combination drug. This includes the various combinations of the two active ingredients (Metamizole and Temazepam) that are marketed.

Q: What happens if I stop taking Tempas suddenly?

According to official warnings, stopping this medication suddenly can lead to serious and potentially life-threatening withdrawal symptoms. These reactions may include seizures, severe tremors, stomach cramps, and a return of severe sleep disturbance (rebound insomnia).

Q: Is it normal to feel a change in appetite while on Tempas?

Official side effect documentation indicates that changes in appetite have been reported. This may include either an increase or a decrease in appetite, and related changes in weight have also been observed as an adverse reaction.

Q: Are there any known long-term side effects of Tempas?

Official product warnings state that using the medication for long periods increases the risk of developing physical dependence and severe withdrawal symptoms. Additionally, due to the risk of a serious blood disorder, regular blood monitoring may be necessary during long-term use, as noted in the label.

Q: Can Tempas cause changes in mood or behavior?

Yes, the official labeling includes warnings regarding potential abnormal thinking and behavioral changes. These serious adverse events have included reports of agitation, hallucinations, confusion, and the worsening of pre-existing depression or suicidal thoughts.

Q: Does Tempas affect blood pressure readings?

Official safety data indicates that this medication has been associated with changes in blood pressure readings. Reports include hypotension (a drop in blood pressure) and, less frequently, mild increases in systolic blood pressure.

Q: Does taking Tempas require any routine lab tests?

Official regulatory documents indicate that routine blood cell count monitoring may be necessary for patients using this drug. This is typically required to watch for signs of Agranulocytosis, a serious blood disorder, especially if a patient experiences symptoms like a high fever or sore throat.

Q: What if I'm taking multiple other medications—is Tempas still suitable?

The official interaction profile indicates that this drug can interact with many other medications. Regulatory documents stress the importance of a healthcare review of all current prescription, over-the-counter, and herbal products to determine suitability before starting treatment.

Q: Is Tempas known to interact with herbal supplements?

Regulatory documents indicate caution is necessary when combining Tempas with all herbal supplements. This is especially true for products that affect the central nervous system, where potential interactions could either increase the side effects or reduce the intended effect of Tempas.

Q: Can I drive or operate machinery while taking Tempas?

No. Official product warnings state that driving or operating heavy machinery must be avoided during treatment. This is due to the risks of extreme drowsiness, reduced alertness, and impaired motor coordination caused by the medication.

Q: Is Tempas safe for someone with a history of heart issues?

Official regulatory warnings indicate that the drug's use is cautioned for patients who have a history of heart issues. This is because both active components are documented to have known cardiovascular side effects, including changes in heart rate and blood pressure.

Q: Do certain genetic factors affect how Tempas works?

While official documents do not explicitly use the term 'genetic factors,' pharmacokinetic studies indicate that the rate at which the body processes the medication can vary significantly between individuals. This variation is influenced by body composition and the natural activity of certain metabolic enzymes.

Q: What is the typical timeframe for seeing the full intended effect of Tempas?

The full intended effect of this medication is based on its indication for short-term use. Clinical trials that established the drug's efficacy typically evaluated its full effect over a treatment period of 7 to 10 consecutive nights of use.

Q: Are there any known interactions between Tempas and caffeine?

Official product information does not include a specific caution regarding caffeine consumption. However, the use of any substance that acts as a nervous system stimulant may reduce or counteract the intended sedative and hypnotic effects of the medication.

Q: Does Tempas affect birth control effectiveness?

Yes. Official interaction documentation states that one of the active components is a strong inducer of liver enzymes (CYP3A4). This can significantly reduce the concentration of hormonal contraceptives in the blood, creating a potential risk for contraceptive failure.

Q: Are there specific symptoms that signal a side effect is serious?

Yes. Regulatory warnings indicate that the development of certain severe symptoms requires immediate medical evaluation. These include a high fever, sore throat, or mouth ulcers (signs of a potential blood disorder) or difficulty breathing, or swelling of the face and throat (signs of a severe allergic reaction).

Q: Are there any reports of weight changes linked to Tempas?

Weight loss is officially listed in the documentation as an uncommon adverse reaction associated with the use of this medication. Related changes in appetite have also been reported.

How should Tempas be stored and disposed of?

Tempas must be stored strictly according to its official label to maintain efficacy and safety.

Category	Requirement
Storage Temperature	Controlled Room Temperature (20 C to 25 C), protected from excessive heat and direct sunlight.
Protection & Handling	Store in the original, tightly closed, light-resistant container. Keep the product in a dry place.
Child Safety	Keep out of the sight and reach of children and pets, preferably in a securely locked cabinet or safe.
Disposal	Drug Take-Back Programs are the preferred disposal method. If unavailable, mix with an undesirable substance, place in a sealed container, and discard in household trash after removing all personal information from the label.

Tempas